Introduction
============

Hyperbaric oxygen therapy (HBOT) represents a possible therapy for both acute ischemic stroke and intracerebral hemorrhage. The potential benefits of HBOT include increased oxygen delivery, decreased cerebral edema, decreased lipid peroxidation, inhibition of leukocyte activation, and maintenance of blood--brain barrier integrity.[@b1-ndt-13-421]--[@b3-ndt-13-421] HBOT was proved to reduce the volume of brain infarction and improve outcome in both mice and rat stroke models with hyperglycemia or diabetes.[@b4-ndt-13-421]--[@b6-ndt-13-421] Despite beneficial results in several animal models,[@b7-ndt-13-421],[@b8-ndt-13-421] the effectiveness in human stroke is still controversial. It was reported that a 56-year-old Chinese patient suffering from acute ischemic stroke on the left corona radiata leading to right hemiparesis and dysarthria had great improvement after repetitive (10 dives) HBOT with lower pressure (2.0 ATA) and short duration (60 min).[@b9-ndt-13-421] In recent years, there have been a few randomized controlled trials in humans as well, but with different strategy as control.[@b10-ndt-13-421]--[@b12-ndt-13-421]

This study aims to determine the insulin-sensitizing effect of HBOT in type 2 diabetes patients suffering from intracerebral hemorrhage. In addition, the efficacy, safety, and feasibility of hyperbaric oxygen at 2.5 ATA were prospectively evaluated.

Methods
=======

This study was a randomized, prospective, normobaric oxygen therapy (NBOT)-controlled pilot study to investigate the potential effect of HBOT on peripheral insulin sensitivity in type 2 diabetes patients with intracerebral hemorrhage. Subjects were randomized according to their time stratum to receive either HBOT or NBOT. Treatment designation was placed in a sealed envelope and seen only by the hyperbaric nurse at the time of treatment. This study was approved by the Zhejiang Medical Institutional Ethics Committee. Before enrollment, written informed consent was obtained from the patients or their next of kin prior to initiation of any clinical procedures that were performed solely for the purpose of determining eligibility for research.

Participants
------------

Participants included adults aged 18 years presenting to an emergency department within 24 h after stroke onset with a measurable deficit on the National Institutes of Health Stroke Scale (NIHSS) and with evidence of hemorrhage on computerized tomography (CT) scan. Patients were excluded if they were not diabetes patients before onset, had a stroke within 3 months, had an NIHSS score \>22, or died within the whole period of 6 months of follow-up. Patients were also excluded if they had risk factors for HBOT, including a history of sickle cell disease, bowel obstruction, severe chronic obstructive pulmonary disease, pneumothorax, or evidence of cardiac arrhythmia deemed by an investigator as potentially mandating emergent intervention.

Interventions
-------------

Fifty-two type 2 diabetes subjects were randomized to receive either HBOT (n=23) or NBOT (n=29). The HBOT group underwent a 60-min continuous treatment once a day for 30 days in a monoplace HBOT chamber pressured with 100% oxygen to 2.5 ATA (50 ft of seawater). The NBOT group underwent similar treatment except with a pressure of 1.5 ATA (4.48 ft of seawater). The NBOT group treatment was designed to simulate pressure changes within the tympanic membrane.

Outcome measures
----------------

Testing was undertaken at approximately the same time each morning, and sampling was undertaken at a similar time each visit. Baseline assessments were performed before intervention. Early (∼10 days after onset) and late (1 month after onset) outcomes (neurobehavioral NIHSS scores) and efficacy (changes in NIHSS scores) of HBOT were evaluated. The criteria of NIHSS score are displayed in detail in [Figure 1](#f1-ndt-13-421){ref-type="fig"}.

The 3.5-h hyperinsulinemic euglycemic clamp was performed at baseline, 1 month and 6 months after onset. All tests were performed in normobaric room air, outside the hyperbaric chamber, as previously described.[@b13-ndt-13-421] Briefly, two intravenous cannulae were inserted into veins on opposite arms. One cannula was connected to an infusion of insulin at a fixed rate of 80 mU m^−2^ min^−1^, together with a variable-rate infusion of 25% dextrose. The other cannula allowed blood sampling every 5--10-min to assess blood glucose levels by a hand-held glucometer. The target blood glucose level was 6 mmol L^−1^. Insulin sensitivity was calculated from the glucose infusion rate (GIR) at the end of the 3.5-h clamp. In addition, serum insulin and hemoglobin A1c (HbA1c) were measured. To avoid any physical effort that might influence glucose uptake, the participants remained sedentary in a chair.

Statistical analysis
--------------------

SPSS version 16.5 was used to perform all statistical analyses. Baseline patient characteristics were compared using either the Wilcoxon rank-sum test or Fisher's exact test. Baseline categorical variables were analyzed by Fisher's exact test, whereas numerical variables were analyzed by Student's *t*-test (equal variance test). Differences between groups were analyzed using one-way analysis of variance (ANOVA). To compare paired data, the Shapiro--Wilk test and the Wilcoxon signed-rank test were used to test the data of clinical responses. Variables in both groups (eg, changes in NIHSS scores) were compared by equal variance test for early efficacy and by the Mann--Whitney *U*-test for late efficacy. A significance level of *P*\<0.05 was used for determining statistical significance.

Results
=======

From August 2012 to June 2016, 52 patients were recruited, including 23 in the HBOT group and 29 in the control group. Their baseline properties and clinical characteristics were compared and analyzed, with no statistically significant difference between the two groups in each item (gender, age, body mass index, triglycerides, total cholesterol, and homocysteine, as shown in [Table 1](#t1-ndt-13-421){ref-type="table"}).

A significant increase was observed in the change in insulin sensitivity during the HBOT sessions ([Figure 2A](#f2-ndt-13-421){ref-type="fig"}, 0 day vs 30 days: 37.2±5.8 vs 51.2±4.9, *P*\<0.05). Conspicuous decreases in the changes in fasting glucose, insulin, and HbA1c were also observed in the HBOT group after 30-day sessions (fasting glucose: 11.3±1.5 vs 9.6±1.1, *P*\<0.05; insulin: 22.9±4.1 vs 17.8±2.6, *P*\<0.05; HbA1c: 9.2±1.6 vs 7.8±1.3, *P*\<0.05; [Figure 2B--D](#f2-ndt-13-421){ref-type="fig"}).

In the HBOT group, the paired *t*-test was used to compare the NIHSS scores before and after HBOT in each group. The NIHSS scores were prominently decreased at both 10 days (mean ± SD, 9.2±1.6) and 1 month after HBOT (8.1±0.8) compared to the pre-HBOT data at baseline (13.5±2.2, *P*\<0.01; [Figure 3B](#f3-ndt-13-421){ref-type="fig"}). In the control group, the scores were evaluated as an obvious decrease only at 1 month after HBOT compared with baseline (8.7±2.1 vs 12.1±2.7, *P*\<0.05; [Figure 3A](#f3-ndt-13-421){ref-type="fig"}). The difference in baseline NIHSS scores between the HBOT group and the control group during the entire treatment period was not statistically significant (*P*\>0.05). However, the efficacy of HBOT in both early and late outcomes resulted in a statistically significant difference between the groups (*P*\<0.05; [Figure 3C](#f3-ndt-13-421){ref-type="fig"}).

Discussion
==========

The results of this study suggest that HBOT at 2.5 ATA for 1 h once a day in diabetes patients with intracerebral hemorrhage seems to be efficacious and beneficial in improving insulin sensitivity, and the efficacy of therapy is more obvious later in the disease course. A comparison of HBOT before and after treatment revealed that the HBOT group had better outcome in a long-term intervention. All patients in the HBOT group showed improvement, except for one patient who presented with worse outcome after 10 repetitions of HBOT (NIHSS score from 10 to 12), but no more disease progression after 1 month (NIHSS score from 12 to 12). Although the early efficacy of HBOT did not reach statistical significance, it still did reveal the tendency of better outcome compared to the control group. A few possible reasons could be explained as follows: 1) the mechanisms of HBOT are to (ie, protection of the blood--brain barrier) repair and generate new blood vessels for the injured part of brain and to improve metabolism after stroke.[@b13-ndt-13-421] It is a long-time effect. 2) Cerebral edema occurs directly after stroke onset and peaks at ∼24--96 h. It decreases blood flow and influences oxygen delivery.[@b14-ndt-13-421] 3) Since HBOT is an adjunctive treatment for stroke, patients during the acute stage commonly receive other treatments such as anti-inflammation therapy and/or antioxidants. Therefore, HBOT may not show its adjunctive effect significantly in mild stroke. 4) Finally, the patients included in this study are of mild severity. The degree of improvement of moderate-to-severe stroke may be more obvious than that of mild one.

As an interventional therapy, it is difficult to identify whether HBOT is more beneficial for patients with stroke only or for patients with both diabetes and stroke. It was observed that as a strong negative prognostic indicator in stroke, patients with admission hyperglycemia commonly showed poor clinical outcome with distinctly lower modified Rankin Scale scores and higher mortality compared to those without admission hyperglycemia.[@b15-ndt-13-421] Another clinical trial reported that hemoglobin A1c level was relatively higher in acute ischemic stroke patients with diabetes and that the risk of mortality and poor outcome showed a tendency to increase with increasing HbA1c tercile.[@b16-ndt-13-421] All we know currently is that a significant time effect was observed in the change in insulin sensitivity during the HBOT sessions in both patients with or without diabetes, although significant reductions in fasting glucose during HBOT sessions were observed only in those with type 2 diabetes.[@b17-ndt-13-421]

The major limitation was that this study was designed as a pilot study with a small number of patients, making its generalizability difficult. Although we originally proposed to enroll more patients in each group, the large workload and caseload limitation finally made us change the proposal.

There are several possible explanations for the results presented in this study. Diabetes patients with intracerebral hemorrhage may benefit from being treated within 24 h of symptom onset, considering the short therapeutic time window. Other explanations may be that the treating period applied in this study was relatively longer than that in other studies.[@b7-ndt-13-421],[@b11-ndt-13-421],[@b12-ndt-13-421] A previous study showed that insulin sensitivity in overweight men with type 2 diabetes was improved following HBOT.[@b13-ndt-13-421] Another study presumed that hyperbaric oxygen might decrease blood glucose levels in patients with diabetes mellitus, stroke, or traumatic brain injury during treatment.[@b14-ndt-13-421] However, all recent studies were based on animal studies or were pilot trials with a small sample size. In animal model studies, HBOT with 2.5 ATA resulted in decreased lipid peroxidation, decreased leukocyte activation,[@b2-ndt-13-421] and improved integrity of the blood--brain barrier.[@b3-ndt-13-421]

Conclusion
==========

Our protocol of HBOT at 2.5 ATA was safe and feasible and appeared to be an efficacious treatment for acute stroke. Based on these results, a study on HBOT with a larger sample size is warranted.
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![The influence of HBOT (n=23) and NBOT (n=29) on (**A**) glucose infusion rate; (**B**) fasting glucose; (**C**) insulin; (**D**) hemoglobin A1~C~ in type 2 diabetes patients suffering from intracerebral hemorrhage.\
**Notes:** All data were presented as mean ± standard deviation. Compared to the value before treatment, \**P*\<0.05, \*\**P*\<0.01.\
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![The clinical outcome (NIHSS score) in the NBOT control (**A**) and HBOT group (**B**); (**C**) the change in NIHSS scores in both groups.\
**Note:** \**P*\<0.05, \*\**P*\<0.01.\
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###### 

Baseline characteristics in two groups

  Indicators                    NBOT (n=29)         HBOT (n=23)         *P*-value
  ----------------------------- ------------------- ------------------- -----------
  Age, median (range)           69 (44--85)         65 (40--83)         0.95
  Female, n (%)                 9 (31.0)            8 (34.8)            0.99
  Body mass index (kg/m^2^)     30.6 (27.7--34.9)   30.9 (30.1--35.7)   0.99
  NIHSS score, median (range)   8 (3--17)           7 (2--20)           0.93
  Glucose (mmol/L)              9.8 (8.1--13.0)     9.3 (7.7--12.8)     0.95
  Triglycerol (mg/dL)           137 (54--388)       165 (57--419)       0.86
  Total cholesterol (mg/dL)     183 (118--292)      202 (124--281)      0.82
  Homocysteine (µmol/L)         11.8 (5.9--16.2)    11.3 (3.3--20.6)    0.98

**Abbreviations:** NBOT, normobaric oxygen therapy; HBOT, hyperbaric oxygen therapy; NIHSS, National Institutes of Health Stroke Scale.
